Maze Therapeutics, Inc. — Director's Dealing 2026

Feb 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Maze Therapeutics, Inc. (MAZE)
CIK: 0001842295
Period of Report: 2026-01-29

Reporting Person: Dandekar Atul (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-29	Common Stock	M	7500	$10.42	Acquired	18003	Direct
2026-01-29	Common Stock	S	1200	$43.1844	Disposed	16803	Direct
2026-01-29	Common Stock	S	3500	$44.0419	Disposed	13303	Direct
2026-01-29	Common Stock	S	2800	$45.0080	Disposed	10503	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-29	Stock Option (Right to Buy)	$10.42	M	7500	Disposed	2031-04-11	Common Stock (7500)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive.

F5: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.